WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the laun...
Biofrontera Inc. (NASDAQ:BFRI ) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer,...
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...
WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will repor...
WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced th...
WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce...
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves....
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript...
(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets) Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBU...
Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company spec...
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will rep...